6-MAPDB, formally known as 1-(2,3-dihydrobenzofuran-6-yl)-N-methylpropan-2-amine, is a chemical compound with potential entactogenic properties. It shares structural similarities with substances like 6-APDB and 6-MAPB, both of which are known to produce effects akin to MDMA and have been utilized for recreational purposes. It’s worth noting that 6-MAPDB has not undergone extensive pharmacological studies to establish its specific activity. However, it is worth mentioning that it is the N-methyl derivative of 6-APDB, which is recognized as a selective serotonin releaser.

IUPAC name
CAS Number1354631-81-4
PubChem CID112500534
Chemical and physical data
Molar mass191.274 g·mol−1


In June 2013, 6-MAPDB faced a ban in the UK as a temporary class drug, along with nine other related compounds. It’s essential to note that 6-MAPDB had not been available as a street drug on its own. The ban was instated as a precautionary measure because of concerns that 6-MAPDB might potentially yield effects similar to substances like 6-APB, which had already been widely distributed as recreational drugs. The decision was made to prevent any potential recreational use of 6-MAPDB.


1. What is 6-MAPDB?

6-MAPDB, or 1-(2,3-dihydrobenzofuran-6-yl)-N-methylpropan-2-amine, is a chemical compound that may possess entactogenic properties. It shares structural similarities with substances like 6-APDB and 6-MAPB, which have effects similar to MDMA.

2. Is 6-MAPDB legal?

6-MAPDB was banned in the UK in June 2013 as a temporary class drug. The legal status of 6-MAPDB may vary in different regions, so it’s crucial to check your local laws and regulations.

3. What are the potential effects of 6-MAPDB?

While the exact effects of 6-MAPDB have yet to be widely studied, it is suggested to have entactogenic properties. However, due to its limited research, the specific results may vary among users.

4. Is 6-MAPDB safe to use?

The safety of 6-MAPDB is still being determined due to the lack of comprehensive studies. As with any unregulated substance, using 6-MAPDB can be associated with risks. Its use is generally discouraged.

5. Why was 6-MAPDB banned in the UK?

6-MAPDB was temporarily classified as a controlled substance in the UK in 2013. This preemptive ban was based on concerns that it could produce effects similar to other substances like 6-APB, which had already been sold recreationally. The ban was enacted as a preventive measure.

6. Can 6-MAPDB be detected in drug tests?

The detectability of 6-MAPDB in drug tests may depend on the specific test and its substances screened for. To avoid potential legal and employment issues, it’s advisable to refrain from using substances with uncertain legal status.

7. What should I do if I suspect someone is using 6-MAPDB or similar substances?

If you suspect someone is using designer drugs or facing substance abuse issues, encourage them to seek professional help and support. Reach out to healthcare providers, counselors, or addiction specialists for guidance.

8. Are there harm reduction strategies for using substances like 6-MAPDB safely?

Harm reduction strategies are essential when dealing with psychoactive substances. Prioritize safety, informed decision-making, and responsible use. Seek guidance from harm reduction organizations or healthcare professionals to minimize risks when using substances like 6-MAPDB.

9. Where can I find more information about 6-MAPDB?

For reliable information on 6-MAPDB and similar compounds, consult reputable sources, scientific literature, government health agencies, and harm reduction organizations. Stay informed and make responsible choices.

10. Is there any ongoing research on 6-MAPDB?

As of my last knowledge update in September 2021, research on 6-MAPDB needed to be improved. It’s advisable to check the latest scientific literature and sources for any updates on ongoing studies or research regarding this compound.


  1. Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (November 1993). “Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine”. Journal of Medicinal Chemistry. 36 (23): 3700–6. doi:10.1021/jm00075a027. PMID 8246240.In November 1993, an insightful study conducted by Monte, Marona-Lewicka, Cozzi, and Nichols explored the synthesis and pharmacological assessment of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. This research offered valuable insights into related chemical compounds.
  2. “Temporary class drug order on benzofury and NBOMe compounds – letter from ACMD”. UK Home Office. 4 Jun 2013. Retrieved 2013-07-11.On June 4, 2013, the UK Home Office released a letter addressing the temporary class drug order on benzofury and NBOMe compounds, as advised by the Advisory Council on the Misuse of Drugs (ACMD). This regulatory action report highlights measures taken concerning these substances at that time.

Leave a Comment

Your email address will not be published. Required fields are marked *